SEC proposes civil charges against Clovis over handling of ditched lung cancer drug
admin 11th April 2018 Uncategorised 0Just three days after celebrating another FDA approval for its ovarian cancer drug Rubraca, Clovis Oncology disclosed trouble with the feds. The SEC is zeroing in on Clovis’ once-promising therapy rociletinib, which went down in flames in 2015—and whether the company was up front about the drug’s problems.
More: SEC proposes civil charges against Clovis over handling of ditched lung cancer drug
Source: fierce